ClinicalTrials.gg
CompletedNCT02896192Updated Sep 21, 2023Results posted

Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity

A Phase 3 interventional study of Setmelanotide and Placebo in Pro-opiomelanocortin (POMC) Deficiency Obesity, sponsored by Rhythm Pharmaceuticals, Inc.. Completed at 7 sites in 7 countries. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2023-09-21.

Sponsored by Rhythm Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing setmelanotide in Obesity — 1 open to participants now, 2 under way, none of them phase 3. setmelanotide · Obesity.

Enrollment
11th of 16
15 · median 34
Started
2017
with 2 others
Phase 3
6 of 16
none open now
Registered
5th of 16
by date
Lead sponsor
15 of 16
Rhythm Pharmaceuticals, Inc.

Among the 16 studies testing setmelanotide in Obesity, this one is the 11th largest by enrollment, is one of 3 that started in 2017, is one of 6 in phase 3, and was the 5th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

1 of the 16 studies testing setmelanotide in Obesity is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About setmelanotide

setmelanotide: first FDA approval 2020 (IMCIVREE), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 6 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing setmelanotide in Obesity, or all of them as a file.
02

Study summary

To demonstrate statistically significant and clinically meaningful effects of setmelanotide on percent body weight change in participants with pro-opiomelanocortin (POMC) deficiency or proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency obesity due to rare biallelic or loss-of function mutations at the end of 1 year of treatment.

03

Conditions studied

  • Pro-opiomelanocortin (POMC) Deficiency Obesity

Browse trials for

Keywords

  • POMC deficiency obesity
  • PCSK1 deficiency obesity
  • Setmelanotide
  • RM-493
  • Obesity
  • Melanocortin 4 receptor
  • MC4R pathway
04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Bi-allelic, homozygous or compound heterozygous (a different gene mutation on each allele) genetic status for either the POMC or PCSK1 genes, with the loss-of-function (LOF) variant for each allele conferring a severe obesity phenotype.
  2. Age 6 years and above.
  3. If adult age ≥ 18 years, obesity with (BMI) ≥ 30 kilograms per square meter (kg/m\^2); if child or adolescent, obesity with BMI ≥ 95th percentile for age on growth chart assessment.
  4. Study participant and/or parent or guardian is able to communicate well with the investigator, to understand and comply with the requirements of the study, and be able to understand and sign the written /assent, after being informed about the study.
  5. Female participants of must agree to use as outlined in the protocol. Female participants of non-childbearing potential, defined as surgically sterile (status post-hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) or for at least 12 months (and confirmed with a screening follicular stimulating hormone [FSH] level in the post-menopausal lab range), or have delayed pubertal development and failure to have achieved menarche, do not require contraception during the study.
  6. Male participants with female partners of childbearing potential must agree to a double barrier method if they become sexually active during the study. Male participants must not donate sperm during and for 90 days following their participation in the study.

Exclusion criteria

Exclusion Criteria:

  1. Recent intensive (within 2 months) diet and/or exercise regimen with or without the use of weight loss agents, including herbal medications, that has resulted in weight loss or weight stabilization. Participants may be reconsidered approximately 1 month after cessation of such intensive regimens.
  2. Prior gastric bypass surgery resulting in >10% weight loss durably maintained from the baseline pre-operative weight with no evidence of weight regain.
  3. Diagnosis of schizophrenia, bipolar disorder, personality disorder or other (DSM-III) disorders that the investigator believes will interfere significantly with study compliance.
  4. A Patient Health Questionnaire-9 (PHQ-9) score of ≥ 15.
  5. Any suicidal ideation of type 4 or 5 on the Columbia Suicide Severity Rating Scale (C-SSRS). Any lifetime history of a suicide attempt, or any suicidal behavior in the last month.
  6. Current, pulmonary, cardiac, or oncologic disease.
  7. History of significant liver disease or liver injury, or current liver assessment for a cause of abnormal liver tests (as indicated by abnormal liver function tests, [ALT], aspartate transaminase [AST], alkaline phosphatase, or serum [> 2.0 x (ULN) for any of these tests]) for an etiology other than non-alcoholic fatty liver disease (NAFLD). Thus, any underlying etiology besides NAFLD, including diagnosed non-alcoholic steatohepatitis (NASH), other causes of hepatitis, or history of hepatic cirrhosis will be exclusionary, but the presence of NAFLD would not be exclusionary.
  8. History or presence of impaired renal function as indicated by clinically significant abnormal creatinine, blood urea nitrogen (BUN), or urinary constituents (e.g., albuminuria) or moderate to severe renal dysfunction as defined by the equation \< 30 mL/min.
  9. History or close family history (parents or siblings) of skin cancer or melanoma, or participant history of ocular-cutaneous albinism.
  10. Significant dermatologic findings relating to melanoma or pre-melanoma skin lesions, determined as part of a screening comprehensive skin evaluation performed by a qualified dermatologist.
  11. Participant is, in the opinion of the study investigator, not suitable to participate in the study.
  12. Participation in any clinical study with an drug/device within 3 months prior to the first day of dosing.
  13. Significant to study drug.
  14. Inability to comply with every day (QD) injection regimen.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Setmelanotide

    Participants received titrated doses of setmelanotide once daily, by subcutaneous (SC) injection during titration period for 2 - 12 weeks. Thereafter, participants continued setmelanotide at their specific therapeutic dose for an additional 10 weeks during the open label treatment period. Participants who achieved at least a 5 kilograms (kg) weight loss (or at least 5% weight loss if baseline body weight was \<100 kg) at the end of the open label treatment period, continued into the 8-week double-blind withdrawal period and received 4 weeks setmelanotide and 4 weeks placebo. Following the withdrawal period, participants entered open label treatment period and received setmelanotide to complete approximately 52 weeks (\~1 year) of treatment at a therapeutic dose.

    Drug: Setmelanotide · Drug: Placebo

Interventions

  • Once daily SC injection

    Also known as: RM-493

  • DrugPlacebo

    Once daily SC injection

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year (Pivotal Cohort)

    The percentage of participants who met the ≥ 10% weight loss threshold after approximately Week 52 (\~1 year) of treatment were analyzed.

    Time frame: Week 52

Secondary outcomes

  1. Percentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year (Pivotal + Supplemental Cohort)

    The percentage of participants who met the ≥ 10% weight loss threshold after approximately Week 52 (\~1 year) of treatment were analyzed.

    Time frame: Week 52

  2. Mean Percent Change From Baseline in Body Weight at Week 52

    The mean percent change from baseline in body weight at 52 weeks was analyzed.

    Time frame: Baseline, Week 52

  3. Mean Percent Change From Baseline in Hunger Score (Worst "Most" Hunger in 24 Hours) at Week 52

    The mean percent change in hunger scores for participants ≥12 years of age with leptin receptor (LEPR) deficiency obesity in treatment with setmelanotide was evaluated. Hunger score ranged from 0 - 10 on a Likert-type scale; 0 = not hungry at all and 10 = hungriest possible. On the Daily Hunger Questionnaire, each of the 3 items (average hunger, most/worst hunger, and morning hunger) was scored separately and averaged on a weekly basis. The weekly average hunger score of the daily worst (most) hunger score in 24 hours is the hunger score used to assess this study endpoint.

    Time frame: Baseline, Week 52

  4. Percentage of Participants Who Achieved at Least 25% Improvement in Daily Hunger From Baseline

    The percentage of participants (≥12 years of age) achieving a ≥25% improvement from baseline in hunger score at Week 52 (i.e., after treatment with setmelanotide for 52 weeks at the therapeutic dose) was assessed. Hunger ranged from 0 - 10 on a Likert-type scale; 0 = not hungry at all and 10 = hungriest possible. On the Daily Hunger Questionnaire, each of the 3 items (average hunger, most/worst hunger, and morning hunger) was scored separately and averaged on a weekly basis. The weekly average hunger score of the daily worst (most) hunger score in 24 hours is the hunger score used to assess this study endpoint.

    Time frame: Baseline, Week 52

  5. Absolute Change From Baseline in Waist Circumference at Week 52

    Waist circumference (centimeters) was measured according to the National Heart, Lung, and Blood Institute (NHLBI) criteria. Waist circumference was measured when participants were fasting at approximately the same time at each visit. The absolute change from baseline in waist circumference was assessed.

    Time frame: Baseline, Week 52

  6. Absolute Change in Body Weight (Reversal of Weight Loss) During Double-Blind Placebo-Controlled Withdrawal Period

    A comparison of weight change was evaluated during the 8 week placebo-controlled withdrawal period for each participant, during which each participant received 4 weeks of placebo and 4 weeks active therapy in a blinded fashion.

    Time frame: Baseline, 8-week withdrawal period (up to ~Week 20)

  7. Absolute Score in Daily Hunger Reduction During the Double-Blind Placebo-Controlled Withdrawal Period

    The absolute score in daily hunger during the double-blind placebo-controlled withdrawal period (≥12 Years of Age) was assessed. Hunger ranged from 0 - 10 on a Likert-type scale; 0 = not hungry at all and 10 = hungriest possible. On the Daily Hunger Questionnaire, each of the 3 items (average hunger, most/worst hunger, and morning hunger) was scored separately and averaged on a weekly basis. The weekly average hunger score of the daily worst (most) hunger score in 24 hours is the hunger score used to assess this study endpoint. Lower scores represent lower hunger, higher scores represent greater hunger.

    Time frame: 8-week withdrawal period (up to ~Week 20)

  8. Mean Percent Change From Baseline in Body Mass Index (BMI) at Week 52

    The mean percent change from baseline in BMI was assessed.

    Time frame: Baseline, Week 52

  9. Area Under the Curve (AUC) Change From Baseline in Oral Glucose, Assessed by the Oral Glucose Tolerance Test (OGTT)

    The AUC change from baseline for the OGTT was assessed. The AUC was calculated by the linear trapezoidal method and includes pre-dose and post-dose assessments. At each visit, oral glucose was captured pre-meal, and post-meal at the following times: 30 minutes, 60 minutes, 90 minutes, and 120 minutes. OGTT was not performed for participants with a diagnosis of Type 1 or Type 2 diabetes.

    Time frame: Baseline, Week 52

  10. Change From Baseline in Serum Glucose at Week 52

    Change from baseline in serum glucose at Week 52 was assessed.

    Time frame: Baseline, Week 52

07

Results

Posted Sep 21, 2023
Limitations and caveats
There was no planned comparison to a randomized placebo group given the rarity of monogenic POMC deficiency obesity. To provide support in assessing setmelanotide treatment in this open-label single-arm trial design, individual participants were evaluated during a double-blind placebo-controlled withdrawal phase in which participants served as their own control to assess effects on weight and reported hunger scores.

Participant flow

Participants were enrolled into the pivotal cohort (10 participants) or supplemental cohort (5 participants). Pivotal cohort: Set of participants under study constituted a collection of detailed clinical case reports with a comprehensive baseline and past medical history assessment and complete clinical efficacy, safety and laboratory evaluations conducted for each participant. Supplemental cohort: Any additional participants enrolled were included in supplemental cohort.

Titration Period (2 to 12 Weeks)
Participant flow — Titration Period (2 to 12 Weeks)
MilestoneSetmelanotide
Started15
Treated15
Completed15
Not completed0
Open-Label Period (10 Weeks)
Participant flow — Open-Label Period (10 Weeks)
MilestoneSetmelanotide
Started15
Completed13
Not completed2
Withdrew: Lack of efficacy1
Withdrew: Protocol violation1
Double-Blind Withdrawal Period (8 Weeks)
Participant flow — Double-Blind Withdrawal Period (8 Weeks)
MilestoneSetmelanotide
Started13
Completed13
Not completed0
Open-Label Period (32 Weeks)
Participant flow — Open-Label Period (32 Weeks)
MilestoneSetmelanotide
Started13
Completed12
Not completed1
Withdrew: Lost to follow-up1

Outcome measures

PrimaryPercentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year (Pivotal Cohort)

The percentage of participants who met the ≥ 10% weight loss threshold after approximately Week 52 (\~1 year) of treatment were analyzed.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year (Pivotal Cohort)
percentage of participantsSetmelanotide (Entire Study)
Percentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year (Pivotal Cohort)80.0 (49.31 to 96.32)
Statistical analysis
  • Setmelanotide (Entire Study) · Exact binomial test · p = <0.0001 (One-sided p-value obtained from exact binomial test, testing that at least 5% of participants in the population of interest would achieve 10% weight loss.)
SecondaryPercentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year (Pivotal + Supplemental Cohort)

The percentage of participants who met the ≥ 10% weight loss threshold after approximately Week 52 (\~1 year) of treatment were analyzed.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year (Pivotal + Supplemental Cohort)
percentage of participantsSetmelanotide (Entire Study)
Percentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year (Pivotal + Supplemental Cohort)85.7 (61.46 to 97.40)
Statistical analysis
  • Setmelanotide (Entire Study) · Exact binomial test · p = <0.0001 (One-sided p-value obtained from exact binomial test, testing that at least 5% of participants in the population of interest would achieve 10% weight loss.)
SecondaryMean Percent Change From Baseline in Body Weight at Week 52

The mean percent change from baseline in body weight at 52 weeks was analyzed.

Time frame:
Baseline, Week 52
Reported as:
Mean · percent change
Mean Percent Change From Baseline in Body Weight at Week 52
percent changeSetmelanotide (Entire Study)
Mean Percent Change From Baseline in Body Weight at Week 52-25.83 ± 9.721
Statistical analysis
  • Setmelanotide (Entire Study) · Longitudinal mixed analysis of variance · p = <0.0001 · Least squares mean: -25.73 · 90% CI -28.49 to -22.98
SecondaryMean Percent Change From Baseline in Hunger Score (Worst "Most" Hunger in 24 Hours) at Week 52

The mean percent change in hunger scores for participants ≥12 years of age with leptin receptor (LEPR) deficiency obesity in treatment with setmelanotide was evaluated. Hunger score ranged from 0 - 10 on a Likert-type scale; 0 = not hungry at all and 10 = hungriest possible. On the Daily Hunger Questionnaire, each of the 3 items (average hunger, most/worst hunger, and morning hunger) was scored separately and averaged on a weekly basis. The weekly average hunger score of the daily worst (most) hunger score in 24 hours is the hunger score used to assess this study endpoint.

Time frame:
Baseline, Week 52
Reported as:
Mean · percent change
Mean Percent Change From Baseline in Hunger Score (Worst "Most" Hunger in 24 Hours) at Week 52
percent changeSetmelanotide (Entire Study)
Mean Percent Change From Baseline in Hunger Score (Worst "Most" Hunger in 24 Hours) at Week 52-27.1 ± 28.11
Statistical analysis
  • Setmelanotide (Entire Study) · Longitudinal mixed analysis of variance · p = 0.0005 · Least squares mean: -27.77 · 90% CI -40.58 to -14.96
SecondaryPercentage of Participants Who Achieved at Least 25% Improvement in Daily Hunger From Baseline

The percentage of participants (≥12 years of age) achieving a ≥25% improvement from baseline in hunger score at Week 52 (i.e., after treatment with setmelanotide for 52 weeks at the therapeutic dose) was assessed. Hunger ranged from 0 - 10 on a Likert-type scale; 0 = not hungry at all and 10 = hungriest possible. On the Daily Hunger Questionnaire, each of the 3 items (average hunger, most/worst hunger, and morning hunger) was scored separately and averaged on a weekly basis. The weekly average hunger score of the daily worst (most) hunger score in 24 hours is the hunger score used to assess this study endpoint.

Time frame:
Baseline, Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved at Least 25% Improvement in Daily Hunger From Baseline
percentage of participantsSetmelanotide (Entire Study)
Percentage of Participants Who Achieved at Least 25% Improvement in Daily Hunger From Baseline50.0 (19.29 to 80.71)
Statistical analysis
  • Setmelanotide (Entire Study) · Exact binomial test · p = 0.0004 (One-sided p-value obtained from exact binomial test, testing that ≥ 5% of participants in the population of interest would achieve ≥ 25% improvement in daily hunger score.)
SecondaryAbsolute Change From Baseline in Waist Circumference at Week 52

Waist circumference (centimeters) was measured according to the National Heart, Lung, and Blood Institute (NHLBI) criteria. Waist circumference was measured when participants were fasting at approximately the same time at each visit. The absolute change from baseline in waist circumference was assessed.

Time frame:
Baseline, Week 52
Reported as:
Mean · centimeters
Absolute Change From Baseline in Waist Circumference at Week 52
centimetersSetmelanotide (Entire Study)
Baseline115.48 ± 17.920
Change at Week 52-17.51 ± 9.112
Statistical analysis
  • Setmelanotide (Entire Study) · Longitudinal mixed analysis of variance · p = <0.0001 · Least squares mean: -18.1 · 90% CI -21.27 to -14.88
SecondaryAbsolute Change in Body Weight (Reversal of Weight Loss) During Double-Blind Placebo-Controlled Withdrawal Period

A comparison of weight change was evaluated during the 8 week placebo-controlled withdrawal period for each participant, during which each participant received 4 weeks of placebo and 4 weeks active therapy in a blinded fashion.

Time frame:
Baseline, 8-week withdrawal period (up to ~Week 20)
Reported as:
Mean · kilograms
Absolute Change in Body Weight (Reversal of Weight Loss) During Double-Blind Placebo-Controlled Withdrawal Period
kilogramsSetmelanotide (Double-Blind)
Change after 4 weeks of therapy: Setmelanotide-2.8 ± 2.41
Change after 4 weeks of therapy: Placebo6.2 ± 3.87
SecondaryAbsolute Score in Daily Hunger Reduction During the Double-Blind Placebo-Controlled Withdrawal Period

The absolute score in daily hunger during the double-blind placebo-controlled withdrawal period (≥12 Years of Age) was assessed. Hunger ranged from 0 - 10 on a Likert-type scale; 0 = not hungry at all and 10 = hungriest possible. On the Daily Hunger Questionnaire, each of the 3 items (average hunger, most/worst hunger, and morning hunger) was scored separately and averaged on a weekly basis. The weekly average hunger score of the daily worst (most) hunger score in 24 hours is the hunger score used to assess this study endpoint. Lower scores represent lower hunger, higher scores represent greater hunger.

Time frame:
8-week withdrawal period (up to ~Week 20)
Reported as:
Mean · units on a scale
Absolute Score in Daily Hunger Reduction During the Double-Blind Placebo-Controlled Withdrawal Period
units on a scaleSetmelanotide (Double-Blind)
Setmelanotide4.5 ± 2.57
Placebo6.7 ± 2.22
SecondaryMean Percent Change From Baseline in Body Mass Index (BMI) at Week 52

The mean percent change from baseline in BMI was assessed.

Time frame:
Baseline, Week 52
Reported as:
Mean · percent change
Mean Percent Change From Baseline in Body Mass Index (BMI) at Week 52
percent changeSetmelanotide (Entire Study)
Mean Percent Change From Baseline in Body Mass Index (BMI) at Week 52-27.32 ± 8.971
Statistical analysis
  • Setmelanotide (Entire Study) · Longitudinal mixed analysis of variance · p = <0.0001 · Least squares mean: -27.4 · 90% CI -30.60 to -24.29
SecondaryArea Under the Curve (AUC) Change From Baseline in Oral Glucose, Assessed by the Oral Glucose Tolerance Test (OGTT)

The AUC change from baseline for the OGTT was assessed. The AUC was calculated by the linear trapezoidal method and includes pre-dose and post-dose assessments. At each visit, oral glucose was captured pre-meal, and post-meal at the following times: 30 minutes, 60 minutes, 90 minutes, and 120 minutes. OGTT was not performed for participants with a diagnosis of Type 1 or Type 2 diabetes.

Time frame:
Baseline, Week 52
Reported as:
Mean · minutes*millimoles/liter (min*mmol/L)
Area Under the Curve (AUC) Change From Baseline in Oral Glucose, Assessed by the Oral Glucose Tolerance Test (OGTT)
minutes*millimoles/liter (min*mmol/L)Setmelanotide (Entire Study)
Baseline951.900 ± 464.9342
Change at Week 52-35.284 ± 442.6334
SecondaryChange From Baseline in Serum Glucose at Week 52

Change from baseline in serum glucose at Week 52 was assessed.

Time frame:
Baseline, Week 52
Reported as:
Mean · mmol/L
Change From Baseline in Serum Glucose at Week 52
mmol/LSetmelanotide (Entire Study)
Baseline6.606 ± 5.0024
Change at Week 52-1.527 ± 1.9374

Adverse events

Collected over From first dose up to ~30 days after last dose of study drug (Up to ~ 1 year). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Setmelanotide0/15 (0%)6/15 (40%)15/15 (100%)
Most frequent serious events
Most frequent serious events
EventSetmelanotide
PleurisyRespiratory, thoracic and mediastinal disorders1/15
DepressionPsychiatric disorders1/15
Major DepressionPsychiatric disorders1/15
Panic AttackPsychiatric disorders1/15
Adrenocortical Insufficiency AcuteEndocrine disorders1/15
PneumoniaInfections and infestations1/15
HypoglycaemiaMetabolism and nutrition disorders1/15
Most frequent other events
Showing 10 of 88
Most frequent other events
EventSetmelanotide
Skin HyperpigmentationSkin and subcutaneous tissue disorders15/15
Injection Site ErythemaGeneral disorders12/15
Injection Site OedemaGeneral disorders9/15
Injection Site PruritusGeneral disorders9/15
HeadacheNervous system disorders8/15
NauseaGastrointestinal disorders8/15
VomitingGastrointestinal disorders8/15
Upper Respiratory Tract InfectionInfections and infestations7/15
Melanocytic NaevusNeoplasms benign, malignant and unspecified (incl cysts and polyps)6/15
FatigueGeneral disorders6/15

Baseline characteristics

The Safety Analysis Set (SAS) Population consisted of participants who received any of the study drug injections and had at least one post-dose safety assessment.

Age, Continuous
Age, Continuous(years)Setmelanotide
Mean17.20 ± 7.02
Age, Customized
Age, Customized(Participants)Setmelanotide
< 12 years5
≥ 12 years10
Sex: Female, Male
Sex: Female, Male(Participants)Setmelanotide
Female6
Male9
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Setmelanotide
Hispanic or Latino2
Not Hispanic or Latino11
Unknown or Not Reported2
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Setmelanotide
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White8
More than one race0
Unknown or Not Reported7
Region of Enrollment
Region of Enrollment(Participants)Setmelanotide
Canada1
Belgium2
United States1
France2
Germany7
Spain2
08

Study locations

7 sites
  • Honor Health Research Institute
    Scottsdale, Arizona 85258, United States
  • UZ Gent
    Gent, 9000, Belgium
  • Peel Memorial Hospital
    Brampton, Ontario L6W 2Z8, Canada
  • Institute of Cardiometabolism and Nutrition / Hopital de la Pitié-Salpêtrière
    Paris, 75013, France
  • Charité Campus Virchow-Klinikum / Institute for Experimental Pediatric Endocrinology
    Berlin, 13353, Germany
  • Hospital Universitario Niño Jesús
    Madrid, 28009, Spain
  • University of Cambridge Metabolic Research Laboratories
    Cambridge, CB2 0QQ, United Kingdom
09

References and documents

Publications

  • Clement K, van den Akker E, Argente J, Bahm A, Chung WK, Connors H, De Waele K, Farooqi IS, Gonneau-Lejeune J, Gordon G, Kohlsdorf K, Poitou C, Puder L, Swain J, Stewart M, Yuan G, Wabitsch M, Kuhnen P; Setmelanotide POMC and LEPR Phase 3 Trial Investigators. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol. 2020 Dec;8(12):960-970. doi: 10.1016/S2213-8587(20)30364-8. Epub 2020 Oct 30. PubMed 33137293 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in May 2020, 39 months.

Results were first posted in Sep 2023, 3 years 3 months after primary completion.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 39 months is above that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2016
First posted
Sep 12, 2016
StartActual
Feb 14, 2017
Primary completionActual
May 25, 2020
CompletionActual
May 25, 2020
Results first posted
Sep 21, 2023
Last update
Sep 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02896192
Responsible party
Sponsor
First posted
Sep 12, 2016
Start date
Feb 14, 2017
Primary completion
May 25, 2020
Completion
May 25, 2020
Results posted
Sep 21, 2023
Last update
Sep 21, 2023

Study contacts

David Meeker, MD
study chair · Rhythm Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Setmelanotide

Start the discussion